TDAC

Company Overview — What Does Translational Development Acquisition Corp. Do?

Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector. Trident Acquisitions Corp. was incorporated in 2016 and is headquartered in New York, New York. Translational Development Acquisition Corp. (TDAC) is classified as a micro-cap stock in the Financials sector, specifically within the Trading industry., headquartered in NEW YORK, New York. With a market capitalization of $232M, TDAC is one of the notable companies in the Financials sector.

Translational Development Acquisition Corp. (TDAC) Stock Rating — Hold (April 2026)

As of April 2026, Translational Development Acquisition Corp. receives a Hold rating with a composite score of 35.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.TDAC ranks #1,520 out of 4,446 stocks in our coverage universe. Within the Financials sector, Translational Development Acquisition Corp. ranks #457 of 891 stocks, placing it in the lower half of its Financials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TDAC Stock Price and 52-Week Range

Translational Development Acquisition Corp. (TDAC) currently trades at $10.60. The 52-week high for TDAC is $10.56, which means the stock is currently trading 0.4% from its annual peak. The 52-week low is $10.06, putting the stock 5.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is TDAC Overvalued or Undervalued? — Valuation Analysis

Translational Development Acquisition Corp. (TDAC) carries a value factor score of 39/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 34.15x, compared to the Financials sector average of 14.88x — a premium of 130%. The price-to-book ratio stands at 1.31x, versus the sector average of 1.22x.

At current multiples, Translational Development Acquisition Corp. trades at a premium to most Financials peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Translational Development Acquisition Corp. Profitability — ROE, Margins, and Quality Score

Translational Development Acquisition Corp. (TDAC) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 2.7%, compared to the Financials sector average of 8.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 14.0% versus the sector average of 1.2%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TDAC Debt, Balance Sheet, and Financial Health

Translational Development Acquisition Corp. has a debt-to-equity ratio of 0.0%, compared to the Financials sector average of 121.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.07x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $100,000. Cash and equivalents stand at $47,150.

TDAC has a beta of -0.01, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Translational Development Acquisition Corp. is 98/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

Translational Development Acquisition Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Translational Development Acquisition Corp. reported revenue of $0. Net income for the quarter was $6M. Operating income came in at $-944,538.

In FY 2025, Translational Development Acquisition Corp. reported revenue of N/A. Net income for the quarter was $6M. Operating income came in at $-944,538.

In Q3 2025, Translational Development Acquisition Corp. reported revenue of N/A. Net income for the quarter was $2M. Operating income came in at $-213,658.

In Q2 2025, Translational Development Acquisition Corp. reported revenue of N/A. Net income for the quarter was $2M. Operating income came in at $-221,127.

Over the past 7 quarters, Translational Development Acquisition Corp. has experienced revenue contraction from $0 to $0. Investors analyzing TDAC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TDAC Dividend Yield and Income Analysis

Translational Development Acquisition Corp. (TDAC) does not currently pay a dividend. This is common among smaller companies in the Trading industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Financials dividend stocks may want to explore other Financials stocks or use the stock screener to filter by dividend yield.

TDAC Momentum and Technical Analysis Profile

Translational Development Acquisition Corp. (TDAC) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

TDAC vs Competitors — Financials Sector Ranking and Peer Comparison

Within the Financials sector, Translational Development Acquisition Corp. (TDAC) ranks #457 out of 891 stocks based on the Blank Capital composite score. This places TDAC in the lower half of all Financials stocks in our coverage universe. Key competitors and sector peers include WHITE MOUNTAINS INSURANCE GROUP LTD (WTM) with a score of 62.9/100, OPPENHEIMER HOLDINGS INC (OPY) with a score of 62.6/100, Enact Holdings, Inc. (ACT) with a score of 61.6/100, International General Insurance Holdings Ltd. (IGIC) with a score of 61.3/100, and PARKE BANCORP, INC. (PKBK) with a score of 60.4/100.

Comparing TDAC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TDAC vs S&P 500 (SPY) comparison to assess how Translational Development Acquisition Corp. stacks up against the broader market across all factor dimensions.

TDAC Next Earnings Date

No upcoming earnings date has been announced for Translational Development Acquisition Corp. (TDAC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TDAC? — Investment Thesis Summary

Translational Development Acquisition Corp. presents a balanced picture with arguments on both sides. The quality score of 10/100 flags below-average profitability. The value score of 39/100 indicates premium valuation. Momentum is weak at 39/100, a headwind for near-term performance. Low volatility (stability score 98/100) reduces downside risk.

In summary, Translational Development Acquisition Corp. (TDAC) earns a Hold rating with a composite score of 35.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TDAC stock.

Related Resources for TDAC Investors

Explore more research and tools: TDAC vs S&P 500 comparison, top Financials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TDAC head-to-head with peers: TDAC vs WTM, TDAC vs OPY, TDAC vs ACT.